Overview of prognostic factors in multiple myeloma

Cancer Research Therapy and Control

Volumn 6, Issue 1-4, 1998, Pages 97-99

  San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; CYTOKINE; IMMUNOGLOBULIN A;

BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; KIDNEY FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY; THERAPY; TUMOR VOLUME;

EID: 0032423583     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Blade J., Kyle R.A. and Greipp P. (1996). Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br. J. Haematology, 93, 345-51.
2. Bataille R., Boccadoro M., Klein B., Durie B. and Pileri A. (1992). C- Reactive Protein and β-2 Microglobulin Produce a Simple and Powerful Myeloma Staging System. Blood, 80, 733-737.
3. Facon T., Menard J.F. and Michaux J.L. (1995). Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report of 91 patients. Am. J. Hematol., 48, 71-5.
4. Gahrton G., Tura S. and Ljungman Petal (1995). Prognostic factors in allogeneic bone narrow transplantation for multiple myeloma. Journal Clinical Oncology, 13, 1312-22.
5. Kyle R.A. (1994) Why better prognostic factors are needed. Blood, 83, 1713-16.
6. Liu P., Leong T., Quam L., Billadeau D., Kay N.E., Greipp P., Kyle R.A., Oken M.M. and van Ness B. (1996). Activating Mutations of N-and K-ras in Multiple Myeloma Show Different Clinical Associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88 7, 2699-2706.
7. Pelliniemi T.T., Irjala ?, Mattila K., Pulkki K., Rajamäki A., Tienhaara A., Laakso M. and Lahtinen R. (1995). Immunoreactive Interleukin-6 and Acute Phase Proteins as Prognostic Factors in Multiple Myeloma. Blood, 85, 765-771.
8. San Miguel J.F., García Sanz R. and González M. (1995). A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood, 85, 448-55.
9. Tricot G., Bartologie B., Jagannarth S., et al. (1995). Poor prognosis in multiple myeloma is associated only with partial or complete deletions of Chr 13 or abnormalities involving 11q and not with other Karyotype abnormalities. Blood, 86, 4250-56.
10. Witzig T.E., Gertz M.A., Lust J.A., Kyle R.A., O'Fallon W.M. and Greipp P.R. (1996). Peripheral Blood Monoclonal Plasma Cells as a Predictor of Survival in Patients with Multiple Myeloma. Blood, 88, 1, 1780-1787.